Though 18F-FDG uptake due to benign pathologies is usually less than that of the malignant tumors, some overlap can occur between these two distinct entities. In order to differentiate benign FDG uptake from malignant, the image interpreter should get a detailed patient history (surgical and clinical history, previous and recent therapies, history of trauma etc.) and evaluate all the previously obtained radiological and scintigraphic images of the patient. In case of a need, laboratory tests and/or other imaging methods such as ultrasonography and MRI should be performed, in accordance with other disciplines. Stability of these lesions on follow-up scans is an important clue for benignity.
Key words: 18F-FDG Uptake, Benign Pathologies, Oncological PET/CT Imaging
|
